Scholarlink

<p>Hematopoietic progenitor kinase 1 (HPK1) is a serine/threonine kinase specific to the hematopoietic system. As a member of the mammalian Ste20-related MAP4K kinase family, HPK1 serves as a key negative regulator of T cell-mediated immune responses. It is implicated in the development of human malignancies. Consequently, HPK1 has emerged as a highly promising target for cancer immunotherapy. Inhibition of HPK1 can abrogate its suppressive effects on T cell activation and function. However, HPK1 shares high structural homology with other MAP4K family members, particularly GLK. This poses a major challenge to the development of highly selective inhibitors. Achieving selectivity by distinguishing HPK1 from other family kinases and key T-cell activation kinases is crucial. It helps minimize off‑target side effects and broaden the therapeutic window. This review summarizes advances in HPK1-targeting strategies from 2016 to 2026. Focusing on the structural classes and selectivity optimization mechanisms of highly selective small-molecule HPK1 inhibitors, as well as breakthroughs in the development of proteolysis-targeting chimeras (PROTACs). The structural biology basis underlying HPK1 selectivity regulation is also analyzed. Finally, this review addresses the challenges in developing HPK1-targeted formulations and discusses future research directions, with the aim of providing a reliable reference for the rational design and clinical translation of novel, highly selective HPK1-targeted therapeutic strategies.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From inhibition to degradation: advances in highly selective targeting strategies for HPK1

  • 期刊论文

  • 发表日期：

    2026年7月11日

查看全文
  • Longbin Yu,
  • Rui Yan,
  • Yashi Li,
  • Huijie Wu,
  • Zhe-Shan Quan,
  • Xiaoting Li,
  • Qing-Kun Shen

摘要

Hematopoietic progenitor kinase 1 (HPK1) is a serine/threonine kinase specific to the hematopoietic system. As a member of the mammalian Ste20-related MAP4K kinase family, HPK1 serves as a key negative regulator of T cell-mediated immune responses. It is implicated in the development of human malignancies. Consequently, HPK1 has emerged as a highly promising target for cancer immunotherapy. Inhibition of HPK1 can abrogate its suppressive effects on T cell activation and function. However, HPK1 shares high structural homology with other MAP4K family members, particularly GLK. This poses a major challenge to the development of highly selective inhibitors. Achieving selectivity by distinguishing HPK1 from other family kinases and key T-cell activation kinases is crucial. It helps minimize off‑target side effects and broaden the therapeutic window. This review summarizes advances in HPK1-targeting strategies from 2016 to 2026. Focusing on the structural classes and selectivity optimization mechanisms of highly selective small-molecule HPK1 inhibitors, as well as breakthroughs in the development of proteolysis-targeting chimeras (PROTACs). The structural biology basis underlying HPK1 selectivity regulation is also analyzed. Finally, this review addresses the challenges in developing HPK1-targeted formulations and discusses future research directions, with the aim of providing a reliable reference for the rational design and clinical translation of novel, highly selective HPK1-targeted therapeutic strategies.

Graphical abstract